Sacubitril (49mg), Valsartan (51mg)

Feb 03, 2023

SACUBRIGHT 100 
Sacubitril (49mg), Valsartan (51mg)
Sacubitril/valsartan, the first angiotensin receptor neprilysin inhibitor approved by the Food and Drug Administration for marketing, has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms in patients with chronic heart failure with a reduced ejection fraction.

For further information please contact: info@sterispharma.com

SHARE WITH